- Home
- PGHL vs ACIU Comparison
PGHL vs ACIU Comparison
Compare PGHL & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGHL
- ACIU
- Stock Information
- Founded
- PGHL 2018
- ACIU 2003
- Country
- PGHL Hong Kong
- ACIU Switzerland
- Employees
- PGHL N/A
- ACIU N/A
- Industry
- PGHL
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PGHL
- ACIU Health Care
- Exchange
- PGHL NYSE
- ACIU Nasdaq
- Market Cap
- PGHL N/A
- ACIU 247.4M
- IPO Year
- PGHL 2024
- ACIU 2016
- Fundamental
- Price
- PGHL $0.47
- ACIU $1.87
- Analyst Decision
- PGHL
- ACIU Strong Buy
- Analyst Count
- PGHL 0
- ACIU 2
- Target Price
- PGHL N/A
- ACIU $12.00
- AVG Volume (30 Days)
- PGHL 166.9K
- ACIU 192.4K
- Earning Date
- PGHL 05-21-2025
- ACIU 03-13-2025
- Dividend Yield
- PGHL N/A
- ACIU N/A
- EPS Growth
- PGHL N/A
- ACIU N/A
- EPS
- PGHL N/A
- ACIU N/A
- Revenue
- PGHL $17,166,534.00
- ACIU $30,136,397.00
- Revenue This Year
- PGHL N/A
- ACIU $120.91
- Revenue Next Year
- PGHL N/A
- ACIU $13.82
- P/E Ratio
- PGHL $15.30
- ACIU N/A
- Revenue Growth
- PGHL 56.11
- ACIU 84.51
- 52 Week Low
- PGHL $0.45
- ACIU $1.87
- 52 Week High
- PGHL $107.36
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- PGHL N/A
- ACIU 23.14
- Support Level
- PGHL N/A
- ACIU $1.95
- Resistance Level
- PGHL N/A
- ACIU $2.05
- Average True Range (ATR)
- PGHL 0.00
- ACIU 0.12
- MACD
- PGHL 0.00
- ACIU -0.02
- Stochastic Oscillator
- PGHL 0.00
- ACIU 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.